Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
TYK Medicines, Inc. Class H ( (HK:2410) ) has provided an announcement.
TYK Medicines, Inc. announced it has been granted a Drug Manufacturing License by the Drug Administration of Zhejiang Province, authorising production via trustee manufacturer Asymchem Life Science (Tianjin) Co., Ltd. through January 2031. The company expects the license to underpin long-term capacity and market expansion and to lay a foundation for subsequent commercial production of its cancer therapies, potentially accelerating the delivery of new treatment options to patients, though it cautions there is no assurance its products will ultimately reach the market.
The most recent analyst rating on (HK:2410) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc. is a China-based biopharmaceutical company focused on developing and manufacturing oncology drugs to address unmet medical needs in cancer treatment. The group operates through subsidiaries and leverages external contract manufacturers to support its production capabilities and future commercialisation efforts in domestic and potentially broader markets.
Average Trading Volume: 3,152,622
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.96B
See more data about 2410 stock on TipRanks’ Stock Analysis page.